Overview

Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
0
Participant gender:
Male
Summary
The objective of the study is to identify mechanisms by which compounds found in cruciferous vegetables alter gene expression via epigenetic modifications (changes in gene expression) and may prevent prostate cancer development. The investigators have found that sulforaphane (SFN), an isothiocyanate found in cruciferous vegetables, inhibits histone deacetylase (HDAC) activity in human colorectal and prostate cancer cells.
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Portland VA Medical Center
Collaborators:
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
Oregon State University
Treatments:
Sulforafan
Sulforaphane
Criteria
Inclusion Criteria:

- Men scheduled for a prostate biopsy

- Age 21 years or older

- Signed informed subject consent

Exclusion Criteria:

- Definitive diagnosis with prostate cancer

- Significant active medical illness which in the opinion of the investigator or
clinician would preclude protocol treatment

- Diagnosis of liver disease as noted on the patient problem list or baseline total
bilirubin greater than institutional upper limit of normal

- Subject reported allergy or sensitivity to cruciferous vegetables

- Use of oral antibiotics, with the exception of doxycycline, within three months prior
to randomization

- Use of warfarin or need for therapeutic anticoagulation at time of biopsy or at
anytime during the course of the trial.

- Current oral steroid therapy

- Current therapy with valproate or other pharmacological drugs associated with HDAC
inhibition

- Diagnosed dementia as noted on the patient problem list or other significant mental
illness that may impact the subjects' ability to follow instructions or comply with
the study protocol

- Patient may not be a part of another flagged study

- Patients already taking SFN dietary supplements